Literature DB >> 22457143

Effect of Sangu Decoction () on metastatic bone destruction in rats with mammary cancer.

Bo Deng1, Li-Qun Jia, Fu-Yun Gao, Jian Cui, Huan Li.   

Abstract

OBJECTIVE: To study and evaluate the effect of Sangu Decoction (SGD, ) on the bone destruction due to mammary cancer metastasis.
METHODS: Metastasis rat mammary tumor-1 cells were transplanted into the left hind limb tibia of SD rats to establish the bone metastasis of the mammary cancer model. The modeled rats were treated with SGD for observing its effect on rats' pain behavior, including 50% paw withdrawal threshold (50% PWT) after von Frey fiber stimulation, burden difference of bilateral feet, and thermal withdrawal latency (TWL), with zoledronic acid as the positive control. Moreover, the damage in the tibia sample of rats was scored by an iconographic method, and the bone mineral density (BMD) as well as the bone mineral content (BMC) were estimated.
RESULTS: The model established showed characteristics of mixed metastasis, revealing the manifestations of tumor development, bone destruction, cancerous pain, etc. In the SGD-treated group, 50% PWT was prolonged (8.13 ± 4.76 vs. 2.30 ± 2.19), and TWL was longer (3.48 ± 0.62 s vs. 2.89 ± 0.26 s) than those in the control group, respectively (P<0.05 or P<0.01). Iconographic scoring also showed improvement of BMD (0.134 ± 0.009 vs. 0.120 ± 0.007, P<0.01) and an elevating trend of BMC in the SGD-treated group.
CONCLUSION: SGD could effectively alleviate the cancerous pain of bone metastasis and mitigate the metastasis that cause osteolytic destruction of bone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22457143     DOI: 10.1007/s11655-011-0802-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  10 in total

1.  Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.

Authors:  Katharine Walker; Stephen J Medhurst; Bruce L Kidd; Markus Glatt; Mick Bowes; Sadhana Patel; Kara McNair; Adam Kesingland; Jonathan Green; Otto Chan; Alyson J Fox; Laszlo A Urban
Journal:  Pain       Date:  2002-12       Impact factor: 6.961

2.  Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model.

Authors:  Kazuma Ogawa; Takahiro Mukai; Daigo Asano; Hidekazu Kawashima; Seigo Kinuya; Kazuhiro Shiba; Kazuyuki Hashimoto; Hirofumi Mori; Hideo Saji
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

3.  Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.

Authors:  Martine P Roudier; Steven D Bain; William C Dougall
Journal:  Clin Exp Metastasis       Date:  2006-08-16       Impact factor: 5.150

4.  Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.

Authors:  François Gouin; Benjamin Ory; François Rédini; Dominique Heymann
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

5.  A rat model of bone cancer pain.

Authors:  S J Medhurst; K Walker; M Bowes; B L Kidd; M Glatt; M Muller; M Hattenberger; J Vaxelaire; T O'Reilly; G Wotherspoon; J Winter; J Green; L Urban
Journal:  Pain       Date:  2002-03       Impact factor: 6.961

6.  Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.

Authors:  Panagiotis Tsagozis; Fredrik Eriksson; Pavel Pisa
Journal:  Cancer Immunol Immunother       Date:  2008-02-23       Impact factor: 6.968

7.  Bone cancer pain.

Authors:  Denis R Clohisy; Patrick W Mantyh
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

8.  Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study.

Authors:  Marina E Cazzaniga; Luigi Dogliotti; Stefano Cascinu; Sandro Barni; Roberto Labianca; Silvana Chiara; Pier Franco Conte; Giampietro Gasparini; Lara Pasetto; Valter Torri
Journal:  Oncology       Date:  2007-09-03       Impact factor: 2.935

9.  The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.

Authors:  Hongjun Peng; Yasuyoshi Sohara; Rex A Moats; Marvin D Nelson; Susan G Groshen; Wei Ye; C Patrick Reynolds; Yves A DeClerck
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

10.  Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.

Authors:  Fabrice Journé; Naïma Kheddoumi; Carole Chaboteaux; Hugues Duvillier; Guy Laurent; Jean-Jacques Body
Journal:  Breast Cancer Res       Date:  2008-01-11       Impact factor: 6.466

  10 in total
  1 in total

1.  Effects of sangu decoction on osteoclast activity in a rat model of breast cancer bone metastasis.

Authors:  Bo Deng; Li-Qun Jia; Huang-Ying Tan; Xuan Yao; Fu-Yun Gao; Lin Pan; Jian Cui; Qing Xiang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-06       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.